ArticleJACC. Case reports2026
Myocardial Ischemia in Young Women With Familial Hypercholesterolemia: Similar Presentation and Divergent Treatment Response.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Consequences of Late Diagnosis and Insufficient Cholesterol Treatment in Women With Heterozygous Familial Hypercholesterolemia.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial hypercholesterolemia (FH) is a disorder often underdiagnosed in young women, delaying prevention of premature coronary disease. CASE SUMMARY: We report 2 women with FH and strong family histories of cardiovascular disease who developed early ischemic events. The first patient experienced STEMI followed by NSTEMI with progressive ventricular dysfunction, requiring repeated percutaneous coronary intervention. The second patient presented with unstable angina and severe 3-vessel disease, managed successfully with coronary artery bypass grafting. Both cases highlight the consequences of delayed recognition of FH and the need for systematic risk assessment. DISCUSSION: Timely identification through lipid evaluation, multimodal imaging, and genetic cascade screening is essential to prevent early onset of atherosclerotic cardiovascular disease in patients with FH. These cases demonstrate the advanced coronary burden that may develop in young women when FH remains unrecognized or undertreated. KEY MESSAGE: Incorporating cascade genetic screening with lipid profiling and multimodal imaging may enable the early identification of subclinical atherosclerosis in young women with familial hypercholesterolemia, thereby supporting the initiation of more intensive therapy before ischemia develops.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.